Cabozantinib Dose Skipping as an Alternative to Dose Reductions
NCT07077161
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Renal Cell Carcinoma (RCC)
Interventions
DRUG:
Cabozantinib
Sponsor
dr. Tom van der Hulle